



Alere Partners with BioIQ to Bring Advanced Biometric Screening Access to Hospitals, Health Plans, Pharmacies and Employers using the Alere Cholestech LDX[®] System

Enhanced Screening Capacity Provides Wellness Providers, Hospitals, Health Plans, Pharmacies and their Employers with Real-Time Biometric Results – Facilitating Referrals of At-Risk Employees to Medical Care and Wellness Programs

WALTHAM, Mass., July 6, 2016 – Alere, a global leader in rapid diagnostics, today announced an exclusive partnership with healthcare technology company BioIQ to offer a seamless interface between BioIQ’s software platform, SoftSuite[™] Dx, and the Alere Cholestech LDX[®] System for immediate access to point of care lipid profile and glucose results for employee biometric screening events.

This partnership facilitates the implementation of comprehensive, HIPAA-compliant biometric screening events, and also enhances the testing experience for employees by making the entire screening process – from scheduling to sample collection to tracking progress – readily available on smartphones and tablets through the BioIQ SoftSuite Dx platform.

Increasingly, employers are conducting biometric screenings to help identify at-risk employees and encourage treatment or prevention strategies that help keep them healthy and productive, while reducing the significant economic impact of heart disease and its complications. The BioIQ SoftSuite Dx platform addresses the challenge of employees not being able to participate in on-site screening events by enabling them to be tested at a wide range of healthcare facilities equipped with the Alere Cholestech LDX System, such as physician offices, walk-in clinics, retail pharmacies, and through the eScreen[™] Occupational Health Network (EOHN).

“Linking Alere’s lipid profile and glucose testing system with the most innovative screening software on the market gives wellness providers and employers access to aggregated Alere Cholestech LDX System test results regardless of where the employee is screened,” said Daniella Cramp, Cardiometabolic Global President, Alere. “With access to real-time biometric results, wellness professionals can immediately assess cardiovascular risk factors, counsel at-risk employees, refer them to medical care and encourage enrolment in employer wellness programs. In this way, our partnership with BioIQ enables wellness providers and employers to fully harness the power of point-of-care testing.”

“Our customers know that comprehensive lipid and glucose testing can help keep employees educated, healthy, and productive, so we are delighted to offer the capability to electronically capture test results from the Alere Cholestech LDX System on the BioIQ SoftSuite Dx platform,” said Justin Bellante, CEO, BioIQ. “Providing wellness professionals and individuals with immediate results empowers them to address personal health risks,

while employers use the aggregated data to monitor and design impactful wellness programs for their employee populations.”

About the Alere Cholestech LDX[®] System

The number one choice of healthcare professionals for more than 20 years, the Alere Cholestech LDX System provides rapid determination of cardiovascular risk at the point-of-care through a family of assays that give lab accurate lipid profile and glucose results in five minutes. The Alere Cholestech LDX System is CLIA-waived, portable with results from a fingerstick sample, creating a positive screening experience and enabling providers to obtain immediate and actionable results.

About Alere Toxicology and eScreen

Alere Toxicology and eScreen offer employers an expansive network of occupational health facilities for conducting employment screening events. With more than 3,500 connected collection sites and 4 laboratories nationwide, we process more than 10 million laboratory drug test specimens and distribute more than 100 million rapid testing devices each year. In addition to managing the entire drug screening process from scheduling to collection to reporting, we also offer biometric screening solutions featuring the Alere Cholestech LDX System, automated solutions for regulated test programs (including eDQ[®] driver qualification and Department of Transportation (DOT) compliance services), and web-based ePhysical[®] services that streamline employee physical examinations and simplify the reporting process.

About Alere

Alere believes that when diagnosing and monitoring health conditions, **Knowing now matters.**[™] Alere delivers on this vision by providing reliable and actionable information through rapid diagnostic tests, enhancing clinical and economic health outcomes globally. Headquartered in Waltham, Mass., Alere focuses on rapid diagnostics for infectious disease, cardiometabolic disease and toxicology. For more information on Alere, please visit <http://www.alere.com>.

About BioIQ

BioIQ (www.bioiq.com) is a healthcare technology company that enables organizations to connect with their populations, measure vital health metrics and achieve health improvement goals. BioIQ works with some of the largest employers and health companies in the nation. Since its inception in 2005, BioIQ has launched thousands of successful health improvement programs that serve millions of participants.

###

Media Contacts:

Alere

Jackie Lustig
Senior Director, Corporate Communications
pr@alere.com
(781) 314-4009

Investor Relations Contact:

Juliet Cunningham

Vice President, Investor Relations
ir@alere.com
(858) 805-2232

BioIQ
Pete Desai
Vice President, Corporate Development & Marketing
media@bioiq.com
(805) 504-8586 ext. 538